samedan logo
 
 
 
spacer
home > ebr > autumn 2021 > accelerating biosimilars
PUBLICATIONS
European Biopharmaceutical Review

Accelerating Biosimilars

“This is not the time for small changes and temporary solutions. This is the moment for bold leadership and action, and for following through on commitments. Future generations are depending on us.” – Dr Tedros Adhanom Ghebreyesus, WHO Director-General (1).

It’s Time For Change

Access to healthcare is a significant global challenge – not one restricted to developing or economically poorer countries. In Europe, while most of the population is covered by a public health system, funding into this system varies (from 3% of GDP in Cyprus up to 9.4% GDP in Germany) and significant proportions of the population – ranging from the self-employed to those who are undocumented – are not automatically covered (2). In addition to funding and access issues, healthcare budgets are stretched, and with the ongoing COVID-19 pandemic, many countries are experiencing shortages of healthcare professionals, medicines, and medical equipment, limiting access to primary care and putting patient care at risk (2-3).

Even before the COVID-19 pandemic, patients struggled to receive state-of-the-art treatments, largely due to rising costs of treatment, a health workforce under pressure, and long waiting times (4). Those with chronic diseases are particularly susceptible to pricing issues, with treatment for some illnesses remaining prohibitively expensive. That, alongside indirect costs, such as lost wages, lost productivity, the need for an additional home, or childcare, all add up to a bigger problem.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Georg Feger has 25 years’ of experience in the pharma and biotech industry in senior leadership positions. Currently serving as Executive Vice President, Business Unit, Biosimilars at Fresenius Kabi SwissBioSim, Georg’s experience includes previous senior positions in R&D, manufacturing and supply of biosimilars, NBE technologies, new products discovery, chemistry, manufacturing, and control development for Fresenius Kabi, Merck, Serono, and GSK.

Throughout his career Georg has led the discovery and development of NCEs, NBEs, and biosimilars in oncology, neurology, and autoimmune diseases resulting in two marketed products and several programmes in late stage development and submission. He successfully led international organisations in biotech and pharma including a research site for Merck/ Serono with more than 300 scientists.
spacer
Georg Feger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IBM Research and Arctoris Accelerate Closed Loop Drug Discovery with AI and Cloud

Oxford and Zurich – 13 September 2021 – Life Science Newswire – Today, IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry.
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement